Intracrinology and dehydroepiandrosterone-a new perspective for the use of androgens in hormone replacement therapy in postmenopausal women;Intrakrynologia a dehydroepiandrosteron-nowe spojrzenie na terapeutyczne zastosowanie androgenów w terapii substytucyjnej u kobiet w okresie menopauzy

Ginekologia Polska

Volumn 82, Issue 9, 2011, Pages 690-695

  Perzyło, Katarzyna ^a   Kulik Rechberger, Beata ^b   Gałczyński, Krzysztof ^a   Rechberger, Tomasz ^a  

^a Katedra i Klinika Ginekologii UM w Lublinie   (Poland)

^b Zakład Propedeutyki Pediatrii UM ^*  (Poland)

Author keywords

Dehydroepiandrosteron; Intracrinology; Menopause

Indexed keywords

EID: 80055049774     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Labrie C, Belanger A, Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat vetral prostate. Endocrinology. 1988,123,1412-1417.
2. Labrie F. Intracrinology. Mol Cell Endocrinol. 1991, 78, 113-118.
3. Ibáñez L, Dimartino-Nardi J, Potau N, Saenger P. Premature adrenarche--normal variant or forerunner of adult disease? Endocr Rev. 2000, 21, 671-96.
4. Speroff L, Fritz M. Abnormal puberty and growth problems. In: Clinical gynecologic endocrinology and infertility. Ed. Speroff L, Fritz M. Philadelphia: Lippincott Williams & Wilkins, 2005, 261-399.
5. Remer T, Manz F, Hartmann MF, [et al.]. Prepubertal healthy children's urinary androstenediol predicts diaphyseal bone strength in late puberty. J Clin Endocrinol Metab. 2009, 94, 575-578.
6. Remer T, Manz F. Role of nutritional status in the regulation of adrenarche. J Clin Endocrinol Metab. 1999, 84, 3936-3944.
7. Idkowiak J, Lavery G, Dhir V, [et al.]. Premature adrenarche: novel lessons from early onset androgen excess. Eur J Endocrinol. 2011, 165, 189-207.
8. Migeon C, Keller A, Lawrence B, Shepart T II. Dehydroepiandrosterone and androsterone levels in human placenta. Effect of age and sex: day-to-day and diurnal variations. J Clin Endocrinol Metab. 1957, 17, 1051-1062.
9. Labrie F, Luu-The V, Labrie C, [et al.]. Endocrine and intracrine sources of androgens in women: Inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev. 2003, 24,152-182.
10. Labrie F, Simard J, Luu-The V, [et al.]. Structure and tissue-specific expression of 3 betahydroxysteroid dehydrogenase/5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues. J Steroid Biochem Mol Biol. 1992, 41, 421-435.
11. Luu-The V, Zhang Y, Poirier D, Labrie F. Characteristics of human types 1,2 and 3 17 betahydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition. J Steroid Biochem Mol Biol. 1995, 55, 581-587.
12. Luu-The V, Tremblay P, Labrie F. Characterization of type 12 17 beta-hydroxysteroid dehydrogenase, an isoform of type 3 17β-hydroxysteroid dehydrogenase responsible for estradiol formation in women. Mol Endocrinol. 2006, 20, 437-443.
13. Li Z, Luu-The V, Poisson-Pare D, [et al.]. Expression of enzymes involved in synthesis and metabolism of estradiol in human breast as studied by immunocytochemistry and in situ hybridization. Histol Histopathol. 2009, 24, 273-282.
14. Luu-The V, Belanger A, Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab. 2008, 22, 207-221.
15. Labrie F, Belanger A, Belanger P, [et al.]. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol. 2006, 99, 182-188.
16. Adashi E. The climacteric ovary: a viable endocrine organ. Semin Reprod Endocrinol. 1991, 9, 200-205.
17. Maroulis G, Abraham G. Ovarian and adrenal contributions to peripheral steroid levels in postmenopausal women. Obstet Gynecol. 1976, 48, 150-154.
18. Labrie F, Cusan L, Gomez J, [et al.]. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J Steroid Biochem Mol Biol. 2009, 13, 52-56.
19. Schriock E, Buffington C, Hubert G, [et al.]. Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinal Metab. 1988, 66, 1329-1331.
20. Nestler J, Barlascini C, Clore J, Blackard W. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab. 1988, 66, 57-61.
21. Labrie F, Luu-The V, Labrie C, Simard J. DHEA and its transformation into androgens and estrogens in peripherial target tissues: intracrinology. Front Neuroendocrinol. 2001, 22, 185-212.
22. Labrie F, Diamond P, Cusan L, [et al.]. Effect of 12-month DHEA replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab. 1997, 82, 3498-505.
23. Baulieu E, Thomas G, Legrain S, [et al.]. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging:contribution of the DHE Age Study to a sociobiomedical issue. Proc Natl Acad Sci U S A. 2000, 97, 4279-284.
24. Arlt W, Callies F, Van Vlijmen J, [et al.]. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999, 341, 1013-1020.
25. Diamond P, Cusan L, Gomez J, [et al.]. Metabolic effects of 12-month percutaneus DHEA replacement therapy in postmenopausal woman. J Endocrinol. 1996, 150, 43-50.
26. Labrie F. Drug insight: Brest cancer prevention and tissue- targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab. 2007, 3, 584-593.
27. Li S, Yan X, Belanger A, Labrie F. Prevention by DHEA of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene(DMBA) in the rat. Breast Cancer Res Treat. 1994, 29, 203-217.
28. Labrie F, Luu-The V, Belanger A, [et al.]. Is dehydroepiandrosterone a hormone? J Endocrinol. 2005, 187, 169-196.
29. Luu-The V, Labrie C, Zhao H, [et al.]. Characterization of cDNAs for human estradiol 17β-hydrogenase and assignment of the gene to chromosome 17: Evidence of two mRNA species with distinct 5' termini in human placenta. Mol Endocrinol. 1989, 3, 1301-1309.
30. Geissler W, Davis D, Wu L, [et al.]. Male pseudohermaphroditism caused by mutations of testicular 17 beta-hydroxysteroid dehydrogenase 3. Nat Genet. 1994, 7, 34-39.
31. Dufort I, Rheault P, Huang X, [et al.]. Characteristics of a highly labile human type 5 17 betahydroxysteroid dehydrogenase. Endocrinology. 1999, 140, 568-574.
32. Luu-The V. Analysis and characteristics of multiple types of human 17 beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol. 2001, 76, 143-151.
33. Labrie F, Cusan I, Gomez J, [et al.]. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol. 2008, 111, 178-194.
34. Labrie F, Archer D, Bouchard C, [et al.]. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and a highly efficient treatment of vaginal atrophy. Menopause. 2009, 16, 907-922.
35. Labrie F, Archer D, Bouchard C, [et al.]. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause. 2009, 16, 923-931.
36. Labrie F, Archer D, Bouchard C, [et al.]. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric. 2011, 14, 282-288.